Amycenone

Amycenone is a standardized preparation derived from Hericium erinaceus that concentrates the mushroom's neuroactive constituents. It has been examined specifically through the lens of the inflammation hypothesis of depression, which holds that pro-inflammatory signaling contributes to depressive pathophysiology and that anti-inflammatory interventions can be antidepressant ^[1].

In the defining study, mice given intraperitoneal lipopolysaccharide developed elevated serum tumor necrosis factor-alpha and depression-like behavior. Oral amycenone at 50 to 200 mg per kilogram markedly blocked the TNF-alpha increase, and at 200 mg per kilogram significantly raised the anti-inflammatory cytokine interleukin-10. Behaviorally, amycenone pretreatment significantly reduced immobility time in both the tail-suspension and forced-swim tests, indicating an antidepressant effect, and the reference SSRI paroxetine produced comparable anti-inflammatory and antidepressant changes in the same model ^[1]. The authors concluded that amycenone could serve as a supplement to prevent inflammation-related depression.

These findings sit within a wider body of work in which whole Hericium erinaceus reduced depression and anxiety in humans over four weeks, apparently through mechanisms beyond simple NGF enhancement ^[2], and in which the mushroom's neurotrophic constituents are proposed to converge on CREB and BDNF signaling relevant to mood ^[3]. Amycenone is thus positioned at the intersection of neuroinflammation control and neurotrophic support. Evidence for amycenone specifically is preclinical, and the extract is standardized commercially rather than being a single defined molecule.

Preclinical antidepressant evidence; supportive whole-mushroom human data

Amycenone is derived from the edible Yamabushitake mushroom and, as a food-derived standardized extract, is expected to share the favorable tolerability of Hericium erinaceus, which showed no adverse laboratory effects in human trials. Dedicated human safety data for the amycenone extract itself are limited, and it is not established for use in pregnancy, lactation or as a replacement for prescribed antidepressant therapy; individuals with mood disorders should treat it as an adjunct rather than a substitute for medical care.

Amycenone was developed as a standardized Hericium erinaceus extract and was investigated for antidepressant potential by a Chiba University group led by Kenji Hashimoto, whose 2015 study established its anti-inflammatory and antidepressant effects in a lipopolysaccharide model of depression. The work built on earlier Japanese human studies linking Yamabushitake intake to reduced depression and anxiety.

Amycenone is recognized in the medicinal-mushroom and psychiatric-nutrition literature as a promising natural agent for inflammation-related depression, benefiting from association with a respected depression-research group. It remains a niche, research-stage extract rather than a mainstream antidepressant, and enthusiasm is tempered by the absence of dedicated clinical trials.